MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

Search

Cerus Corp

Geschlossen

BrancheGesundheitswesen

1.57 3.97

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.51

Max

1.6

Schlüsselkennzahlen

By Trading Economics

Einkommen

2M

-5.7M

Verkäufe

9.2M

52M

Gewinnspanne

-10.897

Angestellte

614

EBITDA

2.7M

-3.1M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+198.01% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

43M

291M

Vorheriger Eröffnungskurs

-2.4

Vorheriger Schlusskurs

1.57

Nachrichtenstimmung

By Acuity

50%

50%

152 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Cerus Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Okt. 2025, 14:47 UTC

Wichtige Markttreiber

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

3. Okt. 2025, 14:25 UTC

Wichtige Markttreiber

Shopify Shares Rise as TD Cowen Raises Price Target

3. Okt. 2025, 13:20 UTC

Akquisitionen, Fusionen, Übernahmen

Anglo American Initiates Arbitration Proceedings After Peabody Deal Falls Through

3. Okt. 2025, 12:40 UTC

Wichtige Markttreiber

Alto Neuroscience Shares Rise After Getting FDA Fast-Track Designation

3. Okt. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

First National Financial Gets Ontario Court Approval for Sale to Birch Hill Equity and Brookfield

3. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Okt. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. Okt. 2025, 19:56 UTC

Market Talk

Treasury Yields Have Weekly Loss as Key Statistics Go Unseen -- Market Talk

3. Okt. 2025, 19:52 UTC

Akquisitionen, Fusionen, Übernahmen

This Mini-Berkshire Insurer Looks Cheap After Sale Of California Unit At High Price -- Barrons.com

3. Okt. 2025, 19:21 UTC

Market Talk

Crude Prices End Week Lower Ahead of OPEC Meeting -- Market Talk

3. Okt. 2025, 19:05 UTC

Market Talk

Natural-Gas Futures Face Mild Temperatures -- Market Talk

3. Okt. 2025, 19:04 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock Group Hunts a $20 billion Deal to Get In on the AI Boom -- WSJ

3. Okt. 2025, 18:22 UTC

Market Talk

Bank of Canada Tentative About More Rate Cuts Due to Upside CPI Risks -- Market Talk

3. Okt. 2025, 17:15 UTC

Market Talk

U.S. Oil Rig Count Decreased Last Week -- Market Talk

3. Okt. 2025, 16:26 UTC

Market Talk

Long-Term Treasury Yields Expected to Shrug Off Fed Cut -- Market Talk

3. Okt. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. Okt. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Okt. 2025, 16:16 UTC

Market Talk

Alaska Air, American Airlines Expected to Post Disappointing 3Q Results -- Market Talk

3. Okt. 2025, 16:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Okt. 2025, 16:02 UTC

Market Talk

Airline Industry Bifurcation Likely to Define 3Q Earnings -- Market Talk

3. Okt. 2025, 15:17 UTC

Akquisitionen, Fusionen, Übernahmen

Tech Buyouts Have Heated Up. These 8 Companies Could Be Next. -- Barrons.com

3. Okt. 2025, 14:56 UTC

Market Talk

European Credit Spreads Could Tighten as New Supply Stays Low -- Market Talk

3. Okt. 2025, 14:10 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Okt. 2025, 14:10 UTC

Market Talk

Sanofi Sales Could Miss Forecasts, With Adjusted Profit in Line -- Market Talk

3. Okt. 2025, 13:34 UTC

Market Talk

Natural Gas Futures Down Amid High Supply, Mild Demand -- Market Talk

3. Okt. 2025, 13:29 UTC

Market Talk

Crude Prices Rise Slightly Ahead of OPEC+ Meeting -- Market Talk

3. Okt. 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. Okt. 2025, 13:14 UTC

Market Talk

Brazilian Companies Face Higher Financing Costs, Fitch Says -- Market Talk

3. Okt. 2025, 13:10 UTC

Market Talk

Bitcoin Looks Ripe For Fresh Record High -- Market Talk

3. Okt. 2025, 12:52 UTC

Market Talk

Ferrari Results Secondary to Investor Day -- Market Talk

Peer-Vergleich

Kursveränderung

Cerus Corp Prognose

Kursziel

By TipRanks

198.01% Vorteil

12-Monats-Prognose

Durchschnitt 4.5 USD  198.01%

Hoch 5 USD

Tief 4 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cerus Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

1.3 / 1.36Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

152 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
help-icon Live chat